Does VEDOLIZUMAB Cause Neoplasm malignant? 326 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 326 reports of Neoplasm malignant have been filed in association with VEDOLIZUMAB (ENTYVIO). This represents 0.4% of all adverse event reports for VEDOLIZUMAB.
326
Reports of Neoplasm malignant with VEDOLIZUMAB
0.4%
of all VEDOLIZUMAB reports
41
Deaths
68
Hospitalizations
How Dangerous Is Neoplasm malignant From VEDOLIZUMAB?
Of the 326 reports, 41 (12.6%) resulted in death, 68 (20.9%) required hospitalization, and 7 (2.1%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VEDOLIZUMAB. However, 326 reports have been filed with the FAERS database.
What Other Side Effects Does VEDOLIZUMAB Cause?
Off label use (21,017)
Colitis ulcerative (13,455)
Crohn's disease (9,759)
Drug ineffective (8,424)
Diarrhoea (7,493)
Abdominal pain (6,401)
Fatigue (5,477)
Haematochezia (5,215)
Frequent bowel movements (4,527)
Arthralgia (4,028)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which VEDOLIZUMAB Alternatives Have Lower Neoplasm malignant Risk?
VEDOLIZUMAB vs VELAGLUCERASE ALFA
VEDOLIZUMAB vs VELCADE
VEDOLIZUMAB vs VELETRI
VEDOLIZUMAB vs VELIPARIB
VEDOLIZUMAB vs VEMURAFENIB